云顶新耀(01952)可能收购Hasten Biopharmaceuticals (SG) Pte. Ltd.全部股权

智通财经03-17

智通财经APP讯，云顶新耀(01952)发布公告，于2026年3月17日，公司与Hasten Biopharmaceuticals (Asia) Limited(卖方)订立一份意向书，内容有关可能收购卖方的全资附属公司Hasten Biopharmaceuticals (SG) Pte. Ltd.(目标公司)的全部股权。目标公司为一家于新加坡注册成立的有限公司，主要从事战略性专注于慢性病及急重症...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2620942031?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-17 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620942031","market":"hk","top_or_hot":-1,"title":"云顶新耀(01952)可能收购Hasten Biopharmaceuticals (SG) Pte. Ltd.全部股权","media":"智通财经","content":"<div>\n<p>智通财经APP讯，云顶新耀(01952)发布公告，于2026年3月17日，公司与Hasten Biopharmaceuticals (Asia) Limited(卖方)订立一份意向书，内容有关可能收购卖方的全资附属公司Hasten Biopharmaceuticals (SG) Pte. Ltd.(目标公司)的全部股权。目标公司为一家于新加坡注册成立的有限公司，主要从事战略性专注于慢性病及急重症...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1415082.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>云顶新耀(01952)可能收购Hasten Biopharmaceuticals (SG) Pte. Ltd.全部股权</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n云顶新耀(01952)可能收购Hasten Biopharmaceuticals (SG) Pte. Ltd.全部股权\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-17 21:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1415082.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，云顶新耀(01952)发布公告，于2026年3月17日，公司与Hasten Biopharmaceuticals (Asia) Limited(卖方)订立一份意向书，内容有关可能收购卖方的全资附属公司Hasten Biopharmaceuticals (SG) Pte. Ltd.(目标公司)的全部股权。目标公司为一家于新加坡注册成立的有限公司，主要从事战略性专注于慢性病及急重症...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1415082.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4209","symbol_name":"餐馆","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1415082.html","article_id":"2620942031","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620942031","pubTimestamp":1773753099,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，云顶新耀 发布公告，于2026年3月17日，公司与Hasten Biopharmaceuticals  Limited(卖方)订立一份意向书，内容有关可能收购卖方的全资附属公司Hasten Biopharmaceuticals  Pte. Ltd.的全部股权。目标公司拥有14种慢病领域品牌产品在亚太多个国家和地区的资产权利，包括上市许可持有人权利、商标及广泛的商业化权益。因此，董事认为，可能的收购将补充集团现有的产品管线，并进一步扩大集团在亚太地区的业务规模，从而提升公司股东的回报。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4209":"餐馆","BK1161":"生物科技","BK1574":"生物医药B类股","BK1583":"高瓴概念","SG":"Sweetgreen, Inc.","01952":"云顶新耀"},"translate_title":"Genting Xinyao (01952) Possible Acquisition Hasten Biopharmaceuticals (SG) Pte. Total equity interest in","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1.5,"SG":1.5},"content_text":"智通财经APP讯，云顶新耀(01952)发布公告，于2026年3月17日，公司与Hasten Biopharmaceuticals (Asia) Limited(卖方)订立一份意向书，内容有关可能收购卖方的全资附属公司Hasten Biopharmaceuticals (SG) Pte. Ltd.(目标公司)的全部股权。目标公司为一家于新加坡注册成立的有限公司，主要从事战略性专注于慢性病及急重症领域(尤其是心血管及代谢板块)的处方药品商业化。目标公司拥有14种慢病领域品牌产品在亚太多个国家和地区的资产权利，包括上市许可持有人(MAH)权利、商标及广泛的商业化权益。公司是一家专注于创新药及疫苖开发、制造及商业化的生物制药公司，致力于满足亚洲市场尚未满足的医疗需求。集团一直在寻找合适的投资机会，收购亚太地区前景良好且有稳定回报潜力的制药公司。目标公司拥有14种品牌慢病领域产品在亚太多个国家和地区商业化权益，搭建了可实现价值兑现的创新泛亚太商业化平台，惠及上千万的亚太慢病患者。东南亚地区覆盖大约6亿人口，其慢病管理市场潜力和未被满足的慢病管理需求巨大。而集团管线亦聚焦CKM(心血管、肾脏及代谢)等慢病治疗领域，与目标公司产品及商业化平台具备高效协同、双向赋能的潜力。在过去的3年间，经过不懈努力，集团以肾科产品耐赋康®为重磅产品，已打造出国内领先的慢病创新药商业化平台，并立志成为亚太地区创新药商业化平台的标杆与国际领先的生物制药企业。集团现有的商业化产品耐赋康®、维适平®、依嘉®正陆续在中国大陆以外的亚洲权益区获批新药上市申请(NDA)，进入当地医保覆盖，通过收购目标公司(如能最终达成)，集团将迈出了全球化战略布局的关键一步，不仅有望迅速实现现有产品的海外商业化落地，从而带来海外销售收入的快速增长，还将以“云顶速度”扩张国际商业化版图。因此，董事认为，可能的收购将补充集团现有的产品管线，并进一步扩大集团在亚太地区的业务规模，从而提升公司股东的回报。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620942031","isCrawlerRequest":true}